Edwards Lifesciences Corporation $EW Stock Holdings Boosted by Hsbc Holdings PLC

Posted by Brian Himes on Jun 21st, 2026

Hsbc Holdings PLC grew its position in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 0.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,148,974 shares of the medical research company’s stock after purchasing an additional 15,577 shares during the quarter. Hsbc Holdings PLC’s holdings in Edwards Lifesciences were worth $183,188,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $26,000. Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences during the fourth quarter worth about $27,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth about $25,000. Hilton Head Capital Partners LLC bought a new stake in Edwards Lifesciences in the fourth quarter worth about $28,000. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in Edwards Lifesciences in the fourth quarter worth about $28,000. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In other news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 81,038 shares of company stock valued at $6,683,255. 0.31% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on EW. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research report on Wednesday, April 1st. Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Evercore reissued an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $95.96.

Get Our Latest Research Report on EW

Edwards Lifesciences Stock Performance

Shares of EW opened at $87.51 on Friday. The company has a 50-day moving average of $83.39 and a two-hundred day moving average of $83.14. The stock has a market cap of $50.39 billion, a price-to-earnings ratio of 46.55, a PEG ratio of 2.19 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $89.60.

Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.